10e jaarlijkse ECD Medisch Symposium Barcelona, Spanje
Medisch Symposium Barcelona Groepsfoto 2025
Samenvatting symposium
Ongeveer 54 medische professionals uit 8 landen woonden het jaarlijkse medische ECD-symposium in 2025 bij. Er werden achttien mondelinge abstracts gepresenteerd, samen met nog eens 8 posterpresentaties. Als gastspreker hield Manel Juan, MD, een presentatie getiteld “CAR-T-cell Immunoherapies: driving therapies beyond Hematological Cancers, through the Barcelona model.” Een avondreceptie bood tijd voor discussies ter ondersteuning van huidige en toekomstige samenwerkingen tussen deze zeer deskundige groep artsen en wetenschappers, die allemaal meer wilden weten over de ziekte van Erdheim-Chester.
Programma’s met symposiumagenda
Agenda
| Presenter | Presentation Title & Slides | Video |
|---|---|---|
| Xavier Solanich, Paul Hendrie | Welcome to Barcelona and the 10th Annual Erdheim-Chester Disease International Conference | Watch (1) Watch (2) |
| Manel Juan | CAR-T-cell Immunoherapies: driving therapies beyond Hematological Cancers, through the Barcelona model. | Watch |
| Oshrat Hershkovitz-Rokah | Advanced proteomic profiling for biomarker discovery in Erdheim-Chester Disease | Watch |
| Benjamin Durham | RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition | Watch |
| Julien Haroche | BCL-2 immunohistochemistry expression in patients with histiocytosis | Watch |
| Lindsay Hill | Comparative Genetic Analysis of Primary versus Secondary Histiocytic Sarcoma: A Single Institution Case Series | Watch |
| Carla Isabel Borre | Comparative Efficacy of Frontline Targeted Therapies Versus Chemotherapy in MAPK-Pathway Altered Histiocytic Neoplasms | Watch |
| Francesco Pegoraro | Second cancer in Erdheim-Chester disease | Watch |
| Jerome Razanamahery | Glomeruloid angioma in Erdheim-Chester disease: an atypical skin manifestation associated with elevated VEGF-A | Watch |
| Francesco Catamerò | Treatment Holidays in Patients with Erdheim-Chester Disease Receiving Vemurafenib: A Prospective Pilot Study | Watch |
| Brinda Shukla | Don’t Dish Out Old Therapies: Use of Pegylated-Interferon-Alpha in a case of Erdheim-Chester Disease with congestive heart failure | Watch |
| Eli Diamond | Symptoms, unmet needs, and quality of life in Erdheim-Chester disease: A longitudinal registry-based analysis | Watch |
| Pudis Michal | Diagnostic Impact of 18F-FDG PET/MRI over PET/CT in Histiocytoses: A Prospective Comparative Study | Watch |
| Francesco Pegoraro | Natural history of Erdheim-Chester disease. A preliminary analysis on 1044 patients within the ECDGA network | Watch |
| Mia Poleksic | Erdheim-Chester Disease: Evolving Insights and Improved Survival Over Time | Watch |
| Gaurav Goyal | Real-World Efficacy and Toxicity of MEK Inhibitors in Histiocytic Neoplasms | Watch |
| Jerome Razanamahery | MAPK-kinase mutations and aortic lesions are associated with the distribution of circulating monocytes in histiocytosis | Watch |
| Abdou Malik Da Silva | Deciphering ALK-positive histiocytosis and mimickers using single cell RNAsequencing | Watch |
| Matthew Collin | The clonal origin and evolution of highrisk multisystem histiocytosis in adults | Watch |
| Polyzois Makras | Mapping Erdheim-Chester Disease in Europe through the Core Registry | Watch |
| Jerome Razanamahery | Layers of Complexity: ECD Diagnosis and management in the presence of confounding comorbidities Jerome Razanamahery Dijon University Hospital, Dijon, France Closing Remarks & Student Abstract | Watch |
| Diane Schriner | ECD Global Alliance into the Future | Watch |